News

Velocity Pharmaceutical Development, along with Dr John Nestor, had established Spitfire for the development of SP-1373, a potent GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH). Under the

Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV. Lyndra’s ultra-long-acting dosage form has the potential to improve medication adherence by allowing

The option obtained by MorphoSys gives it the rights to globally develop and commercialise Vivoryon’s family of QPCTL inhibitors, including the latter’s lead compound PQ912. Currently, PQ912 had

ViiV Healthcare said that its team will work with clinical staff at different sites across the US to conduct one-year CUSTOMIZE trial (cabotegravir plus rilpivirine in the US

Fresenius Kabi Levothyroxine Sodium Injection is the first-and-only FDA-approved solution formulation for this medicine available in the U.S. Fresenius Kabi also sells Levothyroxine Sodium for Injection as a

The results, which were presented as a short oral presentation, included preliminary safety and efficacy data from an ongoing multicenter, open-label, dose-escalation study, which aims to determine the

CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India. The aim of the collaboration is

Close to 8,000 participants are being enrolled by BiondVax for the second cohort for the late-stage trial of M-001 in 85 sites across seven countries in eastern Europe.

Pfizer and Sangamo Therapeutics revealed updated results from the Phase 1/2 Alta study, which demonstrated that SB-525 was generally well-tolerated and showed a dose-dependent increase in Factor VIII